Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2022
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Cancer Education
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

Phase 2 study results for Chronic Lymphocytic Leukemia (CLL) patients

6/17/2019

0 Comments

 
Tweet
Combining venetoclax (Veneclexta) + ibrutinib (Imbruvica) may be an effective initial treatment for previously untreated patients with CLL (a.k.a Chronic Lymphoblastic Leukemia), ​results of a Phase II (Phase 2) study by The University of Texas MD Anderson Cancer Center, published on May 29, 2019, suggest.
Both of these drugs are already FDA approved. The study was conducted with 80 previously untreated patients.
  • Median age was 65 years with 30 percent over age 70.
  • Of these patients, 92% had high-risk genetic anomalies.
  • 88% of patients had complete remission with normal or incomplete blood count recovery after 12 cycles of treatment.
  • 61% of patients had complete remission with undetectable minimal residual disease.
  • 60% of patients developed low white blood cell counts, similar to what has been reported in other venetoclax combination trials.
​
According to the researchers, the combination of these two drugs gave substantially better results than each of these two drugs alone. 

The researchers also added that more robust therapies for CLL patients are needed, due to the fact that:
  1. majority of patients are older than 65, and
  2. that the existing therapies are not always effective.

One of the lead researchers, Dr. Jain, said the following: “This group of patients often has unacceptable side effects and has a lower rate of complete remission and undetectable minimal residual disease. Our data showed that non-chemotherapy, combination therapy with ibrutinib and venetoclax demonstrated no new toxic effects compared to what has been previously reported for the individual agents.”

No new safety concerns were observed with the combination therapy.

The current median follow-up of the trial is 14.8 months. However, according to the researchers a longer follow-up is needed to adequately assess the long-term safety of this combination.

Study findings were published in New England Journal of Medicine on May 29, 2019.

Lead researchers of the study included:
  • Nitin Jain, M.D., Associate Professor of Leukemia 
  • William Wierda, M.D., Ph.D., Professor of Leukemia
  • Varsha Gandhi, Ph.D., Department Chair ad interim of Experimental Therapeutics
Phase II study results for Chronic Lymphocytic Leukemia (CLL) patients - Cancer Education and Research Institute (CERI)
References: 
  1. ​Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients. 
  2. Ibrutinib and Venetoclax for First-Line Treatment of CLL, Nitin Jain, M.D., Michael Keating, M.D., Philip Thompson, M.D., et al., N Engl J Med 2019; 380:2095-2103.

#ChronicLymphocyticLeukemia #CLL #ChronicLymphoblasticLeukemia #clinicaltrials #mdanderson #mdandersoncancercenter #leukemia #cancertreatment #venetoclax #Veneclexta #ibrutinib #Imbruvica
0 Comments

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    May 2020
    April 2020
    March 2020
    September 2019
    June 2019
    May 2019
    October 2018
    February 2017
    January 2017
    December 2016
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    January 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013

    Categories

    All
    Cancer News
    Cancer News
    Cancer Research Simplified News
    Crs News
    Crs News
    Holidays
    Quotes

Yes, I'd like to help CERI continue saving lives!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2023 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®